ALL-BFM 95 Treatment in Turkish Children with Acute Lymphoblastic Leukemia-Experience of a Single Center

Koçak Ü., Gursel T., Kaya Z., Aral Y. Z., Albayrak M., Keskin E. Y., ...Daha Fazla

PEDIATRIC HEMATOLOGY AND ONCOLOGY, cilt.29, sa.2, ss.130-140, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 29 Sayı: 2
  • Basım Tarihi: 2012
  • Doi Numarası: 10.3109/08880018.2011.629859
  • Dergi Adı: PEDIATRIC HEMATOLOGY AND ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.130-140
  • Anahtar Kelimeler: acute lymphoblastic leukemia, ALL-BFM 95 protocol, children, DEVELOPING-COUNTRY, TRIAL, PROTOCOL, SURVIVAL, THERAPY, CHINA, INDIA
  • Gazi Üniversitesi Adresli: Evet

Özet

Little is known about the likelihood of curing children with high-dose chemotherapy regimens for treatment of childhood acute lymphoblastic leukemia (ALL) in Turkey. The authors here report their 13 years' experience with original ALL-BFM (Berlin-Franfurt-Munster) 95 protocol in a cohort of 140 Turkish children with ALL. Complete remission rate was 97.7% with a relapse rate of 12.9% and death rate 17.9% during a median follow-up of 69 months. The event-free survival (EFS), disease-free survival (DFS), and overall survival (OS) in these patients at 12 yearswere 75.0%, 87.1%, and 80.6%, respectively. These results show that ALL-BFM95 protocol is equally applicable in the experienced centers, even in developing countries without substantial treatment-related toxicity. High rate of infection deaths are to be reduced with correct policies.